A Predictive Modelling Framework for COVID-19 Transmission to Inform the Management of Mass Events

Claire Donnat

Department of Statistics
University of Chicago, Chicago, USA
cdonnat@uchicago.edu

Freddy Bunbury

Department of Plant Biology
Carnegie Institution for Science, Stanford, USA
fbunbury@carnegiescience.edu

Jack Kreindler

School of Public Health
Imperial College, London, UK
j.kreindler@imperial.ac.uk

Filippos T. Filippidis

School of Public Health
Imperial College, London, UK
f.filippidis@imperial.ac.uk

Austen El-Osta

School of Public Health
Imperial College, London, UK
a.el-osta@imperial.ac.uk

Tõnu Esko

Institute of Genomics
University of Tartu, Tartu, Estonia
tonu.esko@ut.ee

Matthew Harris

School of Public Health
Imperial College, London, UK
m.harris@imperial.ac.uk

Abstract

Modelling COVID-19 transmission at live events and public gatherings is essential to evaluate and control the probability of subsequent outbreaks. Model estimates can be used to inform event organizers about the possibility of super-spreading and the predicted efficacy of safety protocols, as well as to communicate to participants their personalised risk so that they may choose whether to attend. Yet, despite the fast-growing body of literature on COVID transmission dynamics, current risk models either neglect contextual information on vaccination rates or disease prevalence or do not attempt to quantitatively model transmission, thus limiting their potential to provide insightful estimates. This paper attempts to bridge this gap by providing informative risk metrics for live public events, along with a measure of their associated uncertainty. Starting with a thorough review of the literature and building upon existing models, our approach ties together three main components: (a) reliable modelling of the number of infectious cases at the time of the event, (b) evaluation of the efficiency of pre-event screening and risk mitigation protocols, and (c) modelling the transmission dynamics during the event. We demonstrate how uncertainty in the input parameters can be included in the model using Monte Carlo simulations. We discuss the underlying assumptions and limitations of our approach and implications for policy around live events management.

1. Introduction

More than a year after a global, unprecedented cancellation of live events in March 2020, the future of live events and the entertainment industry remains uncertain despite increasing vaccination rates and low community prevalence levels (at the time of writing). The main concern raised by these gatherings lies in their susceptibility to “super-spreading” — a scenario whereby a few contagious participants inadvertently infect a disproportionately large number of others [1, 2, 3, 4, 5, 6]. The role of super-spreading events has been highlighted as a significant driver of the pandemic [7, 8, 9, 10, 11]. Despite the planned re-opening of live events in the UK on June 21st 2021, the threat of existing and emergent COVID-19 variants coupled

Preprint. Under review.

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

to dwindling immunity from vaccination over time suggests that policy makers and event organizers will likely continue to struggle with the following two questions: (a) Is the COVID-19 transmission risk posed by these events tolerable? and (b) What additional safety measures can be feasibly deployed to reduce this risk? The answer to these questions is inherently tied to the estimation of two quantities: *the number of infections occurring at the event*, and *the post-event secondary attack rate*, or number of subsequent infections in the participants' social circles. Evaluating the safety (or lack thereof) of large public gatherings can then be reframed as quantifying the significance and magnitude of their effect on the distribution of the number of primary and secondary COVID-19 cases. Yet, despite the growing body of literature on COVID-19 risk evaluation and recent efforts to evaluate the safety of live events, their effect on COVID-19 transmission remains ill-characterized. Nevertheless, over the past several months, a number of calculators were developed to estimate this risk [12, 13, 14, 15]. These methods can typically be placed in one of three categories.

(a) *Ranking heuristics*: These estimators typically rank events on a scale ranging from “low” to “high” risk based on the feedback of medical experts [13, 16, 17, 18]. However, these heuristics do not take into account any contextual information, including the prevalence, such that the risk associated with the event would be classified as high regardless of whether it was held in August 2020 (background prevalence of 1 in 3,000 individuals) or January 2021 (prevalence of 1 in 60 individuals¹).

(b) *Context-based heuristics*: These calculators estimate the probability of encountering one COVID-case based on the number of people attending an event [12, 13]. Whilst the latter are more context-aware than risk assessment charts, they do not account for modelling transmission dynamics — which is undeniably one of the main unknowns in the spread of viral epidemics — and consequently rarely stratify risk by type of activity. To exemplify, a classical music recital of 1.5 hours for the BBC Proms would potentially be considered equally risky to a 3-hour concert in which participants could be expected to sing along.

(c) *Transmission risk calculators*: Stemming from the physics of fluid dynamics, these calculators focus on modelling the aerosolization and spread of micro-droplets — typically in a closed/indoor environment [19, 20, 21, 22]. These fine-grained models have to be combined with extensive simulations of crowd movements in order to model transmission dynamics during any given event.

Regardless of their category, most of these models rely on a large number and wide range of input parameters, including (but not restricted to) the prevalence of the disease. Whilst certain calculators attempt to bridge the gap between expert heuristics and physical models [12, 23], they are not capable of predicting the risk of a future event. Moreover, all of these estimators provide point estimates — in other words, their output is a single number to quantify the risk. Given the uncertainty associated with all the inputs and the parametrization of the problem, the provision of a single consolidated outcome or number can potentially be misleading. This is because a singular focus on the expected outcome precludes consideration of the distribution of all possible outcomes, including worst-case scenarios.

Mitigating transmission risk. Meanwhile, with the increasing vaccination rates in several countries around the world, a few initiatives have begun to evaluate the outbreak risk associated with live events [24, 25, 26, 27]. This is because vaccinated individuals may still be infected with SARS-CoV-2 [28, 29], and even antigen-test based screening of ticket holders offers no guarantee due to false negatives [30, 31]. The estimation of what constitutes an admissible level of risk thus poses a difficult conundrum to the live event industry. To begin answering these questions, the CAPACITY study [32] — a partnership between CERTIFIC (a private, remote testing, health status and identify certification service), LiveNation (a live events production company) and Imperial College London — aims to predict and measure the outcomes of full capacity live events whilst ensuring rigorous implementation and alignment to current public health and recommended safety measures. Central to this study is the provision of a streamlined and efficient pre-event screening protocol of all ticket holders using professionally-witnessed rapid at-home antigen tests followed by post-event monitoring based on antigen tests, surveys and safety recommendations (see Appendix D). In this setting, providing risk estimates not only becomes essential in communicating to the ticket holders their own level of risk so that they may make an informed decision of whether or not to attend the event, but also necessary to inform event managers and policy makers on the likelihood of an outbreak — a task which serves here as the motivating application behind this paper.

A working example: Concert at the Royal Albert Hall. In order to understand and illustrate the potential challenges that arise in the risk estimation for the CAPACITY study, we consider as an example a concert at the Royal Albert Hall (RAH), and demonstrate how to estimate the associated risk assuming a near-capacity attendance of 5,000 in the main concert hall, which has a volume of 86,650 m³ [33], with a dwell time of 3 hours. Attendees will be assumed to be a cross-section representative of the general British public and will be

¹Source: Office for National Statistics Survey data

required to have a negative COVID antigen test result within 2 days prior to the event, as well as satisfying other self-declared symptoms and exposure-risk questions. Vaccination status would be requested, but not required for attendance, and full compliance with mask wearing is assumed in our default example.

Goals and Contributions. The objectives of our modelling approach are three-fold: (a) enable the quantitative comparison of different activities and event characteristics, (b) estimate the efficacy of various safety protocols and (c) provide a predictive risk assessment, i.e. the risk associated with a scheduled future event. To this end, we delineate our approach into three sequential steps (see Fig. 1) as follows: 1) estimating the number of contagious participants, 2) evaluating the transmission dynamics, and 3) comparing the risk of holding the event with the null model i.e. if the event had not taken place. We illustrate the application of our risk modelling pipeline in the RAH example to highlight the risk’s dependency on factors such as prevalence, mask wearing, number of attendees and event duration. In particular, we demonstrate how this particular event held on three different dates (3rd August 2020, 18th January 2021, 8th March 2021) would likely lead to transmission events only slightly above background rates (0.5 vs 0.2, 6.7 vs 3.5, and 5.4 vs 2.5, respectively (Table 2)). However, the 97.5 percentile of the prediction interval for the infections at the event would likely be substantially higher than the background rate (6.8 vs 2, 89 vs 8, and 71 vs 7, respectively), further demonstrating that sole reliance on vaccination and antigen testing to gain entry would significantly underestimate the tail risk of the event. However, we emphasize that the goal of this paper is not to present a novel “state-of-the-art” risk estimation procedure because COVID-19 transmission mechanisms remain poorly characterized, and we acknowledge that our approach requires certain simplifications and assumptions which we discuss at length in the last section of this paper. Rather, faced with the need to provide a risk evaluation tool despite many unknowns, our estimation pipeline combines the best tools at hand to assess the order of magnitude of the risk – thereby opening the avenue for further work on contextualized COVID risk assessment. Our model can be applied to any event occurring in the near future, and is presented in a user-friendly R Shiny interface².

Figure 1: Summary of our modelling pipeline

2. Modelling The Risk of a Large Public Event

Step 1. Estimating the Number of Infectious Participants

Projected Incidence. The first step in our risk modelling procedure is to predict the number of infectious cases attending a given future event. COVID forecasting is undeniably an involved task, as reflected by its impressive corresponding body of literature (e.g. agent-based models, or Susceptible-Exposed-Infectious-Removed (SEIR) models [34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44]). Predicting the number of new cases per day typically depends on the choice of a specific parameterization (e.g. an exponential growth for computing the reproductive number R [45, 46], etc), whose validity is severely hindered by continuous updates in public policies. To alleviate these concerns, we use a non-parametric k-nearest neighbour (kNN) approach. Using all trajectories of the disease incidence across countries and time since the beginning of the pandemic, we compute the $k = 100$ closest trajectories (in terms of the ℓ_2 loss) on time windows of four weeks. These nearest neighbours’ subsequent trajectories are then used to predict the daily incidence rate in the days leading to the event. We defer to Appendix A for a more in-depth discussion of this estimation procedure, as well as an evaluation of its performance compared to more standard methods. Figure 2 presents a comparison of the projected incidence for various randomly sampled dates (August 3rd 2020, January 18th 2021, and March 8th 2021) for the RAH concert using four weeks of fitting, and predicting four weeks in advance. Note in particular the good coverage provided by our method (the convex hull of the 95% prediction intervals for the

²Link to the prototype: https://homecovidtests.shinyapps.io/aerosol_transmission_model/

Figure 2: Projected incidence (average and 95% prediction interval). The 4 weeks of fitting is denoted in light gray, and the confidence interval for the next four weeks is highlighted in dark gray. We note that our kNN method provides good coverage (the observed trajectory lies well within the 95% prediction interval).

projected incidences contains the actual observations). These plots highlight the importance and variability of the incidence, which varied by orders of magnitude between August 2020 and January 2021.

Under-ascertainment Bias. The estimated number of new cases based on official incidence data will then need to be corrected for under-ascertainment. The latter refers to the downward bias of the reported prevalence in the population, due for instance to limited testing capacity, low test sensitivity or people being unwilling or unable to take a test. To this end, we compare the ratio of the number of deaths over reported cases (translated by three weeks) to an expected, age-stratified Infection-Fatality Ratio³ (see Appendix A for more details). To highlight the potential importance of this correction step, the ascertainment rate for the United Kingdom was evaluated as over 90% for August 2020, but below 40% for December 2020.

Determining the Number of Infectious participants at the event. Having predicted the background daily incidence rate, we turn to the estimation of the number of infectious participants who will attend the event despite the screening protocols. For an infectious individual to attend the event in spite of the CAPACITY study' screening protocol, they must (a) have no COVID-like symptoms or fail to report them on the morning of the event, (b) receive a (false) negative result during antigen testing $D = 2$ days prior to the event, and (c) be contagious (rather than simply infected) at the time of the event. We evaluate the joint probability of these events as follows, and, for the sake of clarity, refer the reader to Appendix A for an in-depth explanation of our estimation procedure.

(a) *Symptoms-Check Failure.* One of the main challenges associated with the COVID-19 crisis is the number of asymptomatic cases – that is, infected individuals that do not express symptoms and are thus unaware of their potential infectiousness. This group includes individuals that are either pre-symptomatic or completely asymptomatic during the course of their illness – the latter are estimated to represent roughly 25% of all cases [47]. For symptomatic patients, the probability of having symptoms on the day of the event is also a function of time since infection. To account for this temporal dependency, we use estimates of the incubation period (defined as the number of days between infection and symptom onset) from McAloon et al. [48] and data on symptoms duration from van Kampen et al. [49] to estimate the probability for a ticket holder infected k days before the event to exhibit symptoms on the day of the event. A density plot of this probability is displayed in red in Figure 3a.

(b) *Antigen test failure.* The sensitivity of COVID tests depends heavily on the time since infection — whether these are the gold-standard PCR or Lateral Flow Antigen Assays [50]. Moreover, studies have shown that LFA tests have much lower sensitivity on asymptomatic individuals than symptomatic: in particular, according to a recent CDC report [51], Rapid Antigen testing has 80% sensitivity on symptomatic individuals, but only 40% sensitivity on asymptomatic individuals. Coupling the sensitivity estimates [50, 51] with the distribution of

³Data available at the following link: <https://github.com/mbevand/covid19-age-stratified-ifr>

Figure 3: (a) Density of the COVID-19 incubation time, and Percentage culture positive. (b) Probability that an individual is infectious (light grey), that the screening protocol will miss them (black), and that they will be missed and so attend the event (red), as a function of days since infection. The shaded regions denote the uncertainty of this estimate due to the uncertainty on the sensitivity of the test. The distribution of the incubation time already integrates the uncertainty on the parameters μ and σ of the log-normal distribution.

incubation period and estimated percentage of asymptomatic cases [48, 47], for each individual infected at day k taking an antigen test D days before the event, the probability of getting through the filtering protocol is thus given by the formula:

$$\begin{aligned} \mathbb{P}[\text{Protocol Fails} | \text{Contaminated at Time } k] = & \underbrace{(1 - s_{t-k-D}^{(\text{symptomatic})})(p_{SC} \times p_{t-k}^{(\text{symptom})} + (1 - p_{t-k}^{(\text{symptom})}))}_{\mathbb{P}[\{\text{Test with Symptom Fails}\} \cap \{\text{Symptom Check Fails}\}]} \\ & + \underbrace{p^{(\text{asymptomatic})} \times (1 - s^{(\text{asymptomatic})})}_{\mathbb{P}[\{\text{Asymptomatic}\} \cap \{\text{Test on Asymptomatics Fail}\}]} \end{aligned}$$

where $s_{t-k-D}^{(\text{symptomatic})}$ and $s^{(\text{asymptomatic})}$ are respectively the sensitivities of the test taken D days before the event for a symptomatic participant infected $t - k$ days before the event and an asymptomatic individual. The parameter $p_{t-k}^{(\text{symptom})}$ denotes the probability for a symptomatic individual to exhibit symptoms $t - k$ days after infection, whereas $p^{(\text{asymptomatic})}$ is the probability of being asymptomatic. Finally, the variable p_{SC} denotes the probability of the Symptoms Check failing — namely, that the participant does not want to report their symptoms (see Appendix A for more details). The curve in black on Figure 3b shows the probability of the failure of the screening protocol as a function of days after infection. The shaded areas denote the uncertainty around this estimate due to the variability of the incubation time.

(c) *Infectiousness*. The infectiousness of the participants — that is, the propensity of an infected ticket holder to contaminate others — is a function of time since infection. In order to estimate this relationship, we build upon the existing literature studying the link between RT-PCR thresholds and cultivable virus [52, 53]. The percentage of culturable viral material in the sample can indeed be used as a proxy for infectiousness. Using the estimated percentages of viable samples [52, 53] as a function of time since symptom onset, compounded with distribution of the incubation period duration [48], we compute an estimate of the infectiousness as a function of time since infection (black curve in Figure 3a). A more complete description of this estimation procedure is presented in Appendix A. The results are presented in Figure 3b. The red line in Figure 3b shows the resulting probability for an infectious ticket holder to pass through the screening protocol and be allowed into the event. Note that ticket holders that have been infected five days before the event are the most likely to be infectious and let in the venue on the day of the event.

Determining the number of participants at risk. Finally, the last quantity that we need to infer before getting into the specifics of the transmission mechanisms is the number of participants at risk of being infected who present at the event. This requires a knowledge of the participants' COVID susceptibility status, i.e., has the participant already had COVID in the previous year and/or has the participant been vaccinated? While previous history could be imputed through additional questions (e.g., previous positive test for COVID, symptoms, etc, combined in a model such as in [54]), for the sake of simplicity, we only consider the vaccination status of the participants — thus leaving out the proportion of the population that had COVID but was not yet

Date of the Event	August 3rd 2020	January 18th 2021	March 8th 2021
Projected incidence	36 in 1,000,000	1,210 in 1,000,000	410 in 1,000,000
Number of Infected Participants	3.3	174	57.5
Number of Infectious Participants at the Event	0.20	10.5	5.3
Percentage of Caught Cases	71 %	69%	62 %
Number of Susceptible Participants	4,996.7	4,826.0	4036.5

Table 1: Comparison of the efficiency of the screening protocol and the number of infectious participants at the event by event date. The combined effect of the screening protocol, and the natural time-dependent infectiousness of infected ticket holders mean that the number of infectious participants at the event is likely to be low, and in the order of tens in times of extremely high prevalence.

vaccinated. This induces a risk estimate that is biased upward, and is thus more conservative. We impute missing data (cases where the participants have not filled in their vaccination status) using linear regression, expressing vaccination rate as a function of time. This assumes that vaccinations are operating at capacity (see Appendix A for a longer discussion on the reasons for this approximation, and further ways of improving this model). Having imputed the rate of new vaccinations $\pi_{s=1\dots t}$ in the days leading to the event, we turn to the estimation of the number of individuals that are likely to be susceptible. Recent reports indicate that vaccine-acquired immunity is a function of both time since vaccination and number of doses [55]. To compute the effective number of participants at risk in the event, we use a compound Poisson distribution: on each day s in the weeks leading to the event, the number X of new participants vaccinated (having either their first or second dose) is expressed as a $\text{Poisson}(\pi_s^{(\text{dose } j)})$, where $j \in \{1, 2\}$. Each of these newly vaccinated individuals then has a probability $\rho_{t-s}^{(\text{dose } j)}$ of being immune, depending on the date and dose j that they have received. The resulting number of immune people Z attending the event thus follows a Poisson model with rate: $Z \sim \text{Poisson}(\sum_{j=1}^2 \sum_{s=1}^T \pi_s^{(\text{dose } j)} \rho_{t-s}^{(\text{dose } j)})$. We discuss in Appendix A how this estimation can easily be modified as the vaccination rates increase and the Poisson approximation becomes no longer valid.

Royal Albert Hall Example For the RAH example, we present a comparison of each quantity for three different dates (see Table 1). Of note is that the screening safety protocol is effective in more than 60% of cases that when combined with the expected infectiousness of participants and self-reporting of COVID-like symptoms, imply that 95% of infected cases are removed. We also note that prevalence is very important in determining the number of infectious cases at the event — thereby highlighting the importance of a context-aware risk calculator.

Step 2. Modelling Transmission Dynamics

Having estimated the number of infectious participants at the event, the second major component of our model consists of estimating the number of transmission events during the event itself.

Identification of transmission mechanisms. More than a year after the start of the epidemic, the precise mechanisms by which COVID-19 is transmitted are still unclear. Aside from direct physical contact, experts continue to debate the significance of the following two main routes of infection:

(a) *Droplet transmission.* In this scenario, transmission happens through the inhalation of droplets (particles of 5 to 10 μm in diameter [56]), and typically occurs when a person is in close proximity (within 1 meter) with someone who has respiratory symptoms (e.g. coughing or sneezing).

(b) *Airborne transmission.* Increasing concerns around airborne transmission have been raised by a number of experts over the past few months [57, 58]. Airborne transmission refers to the presence of the virus within droplet nuclei remaining in the air for long periods of time and with the potential to travel long distances [57] and penetrate more deeply in respiratory tracts. Airborne transmission has been estimated to be nearly 19 times more likely indoors than outdoors [59]. In the context of large public events, this transmission route thus has more diffusive power and hence could explain several super-spreader events (SSEs) [6] making it a major cause for concern [60, 61, 53, 62, 2, 57, 63, 64, 65, 66].

While droplet emission is undeniably a source of concern and a major source of transmission, simple safety precautions such as mask wearing have been shown to efficiently control this transmission source [67, 68]: it is estimated that face masks can block 80% of exhaled droplets and reduce inhaled droplets by up to 50%, and so on average reduce the transmission probability by 70% [67]. Conversely, the evidence concerning the

Date of the Event	August 3rd 2020		January 18th 2021		March 8th 2021	
Scenario	Event	No Event	Event	No Event	Event	No Event
Median	0.5	0.2	20	3.5	5.4	2.5
1st Percentile	0.28	0	11	0	2.9	1
2.5th Percentile	0.28	0	11	0	3.0	1
97.5th Percentile	6.8	1	264	8	71.3	6
99th Percentile	14.6	2	575	8	162	7

Table 2: Quantiles of the number of transmission events for the RAH concert. The grey cells provide the quantiles for the null distribution, that is, a situation in which the event does not take place but ticket holders might still get infected as a by-product of the background community prevalence.

efficiency of standard protective equipment in filtering aerosol droplets varies widely across studies probably due to “variation in experimental design and particle sizes analyzed” [67]. Airborne transmission in indoor settings can thus represent one of the main risk factors in live events, which we focus on modelling using the aerosol model proposed by Jimenez [69, 63]. The Jimenez aerosol transmission model [69, 21, 63, 70] is currently one of the only COVID-transmission models that provides enough granularity to quantify the risk associated with an event. This recognized model has been used several times in the literature over the course of the pandemic, including to allow in-class teaching at the University of Illinois at Chicago [64]. Based on the Wells-Riley model [71, 72, 73], this estimator calibrates the quanta to known transmission events, and takes into account important factors to compute a risk estimate, including event-specific (number of people, local prevalence, etc) and venue-specific variables (ventilation rate, size of the venue, UV exposure). This Wells-Riley-based model relies on the evaluation of three quantities: (a) the quanta exhalation rate, which is contingent on the activity performed and the number of infectious participants; (b) quanta concentration, which is a function of the volume of the space, the room ventilation rate, and the quanta exhalation rate; and (c) quanta inhalation rate, which is a function of the quanta concentration and breathing rate associated with the activity performed. The probability for each susceptible individual to be infected can then be written as: $p_{\text{infection}} = 1 - e^{-q_{\text{inhalation}}}$ (See Appendix B for more details).

Modelling the uncertainty of the model. To estimate the uncertainty associated with this model, we use Monte-Carlo simulations. We simulate random input parameters (number of infectious and susceptible individuals) using the distributions and uncertainty estimates discussed in the previous section. In order to model the uncertainty associated with the Jimenez transmission model, we add a sampling step at the end of the Jimenez pipeline. This allows us to account for individual variations in infectious participants’ ability to spread the disease, and to remain consistent with the extensive literature on the heavy-tailed, Pareto nature of COVID transmission and superspreading [74, 75, 76]. For each susceptible participant, we sample their probability of infection $p_{\text{infection}}$ from a Pareto distribution centered at the computed $q_{\text{inhalation}}$, and with shape $\theta = 1.16$ and rate $\eta = \theta/(\theta - 1)(1 - e^{-q_{\text{inhalation}}})$. This produces a distribution centered around $1 - e^{-q_{\text{inhalation}}}$, but heavily skewed to model variability in the crowd. This choice of parameters allows us to abide by the Pareto principle, according to which 80% of transmissions are due to 20% of those infected.

Step 3. Comparison with the Null Model

To quantify the effect of the event, it is necessary to put it in context of the background rate of infections: even if the participants had not been to the event, they could have been infected elsewhere. In this null model, the number of infections is binomially distributed, such that the number infections Y is $Y \sim \text{Binom}(n_{\text{susceptible}}, \pi)$.

The Royal Albert Hall. We present the results for the RAH example in Table 2. This table shows in gray the values of the different quantiles of this distribution. We note the skewed distribution that we obtain is expected given the modelling of the uncertainty around inhalation rate. If the event did not occur, then on each respective date there would be an expected community transmission of 0.2 (95% prediction interval: 0.00, 1), 3.5 (0.00, 8) and 2.5 (1, 6) events on August 3rd 2020, January 18th 2021 and March 8th 2021, respectively. However, with the event taking place on these dates, and calculating the expected number of infectious individuals, susceptible individuals and transmission dynamics within the venue, the number of transmission events would in general increase to 0.5 (0.3, 6.8), 20 (11, 264) and 5.4 (3.0, 71) in that same order.

It is likely, although not inevitable, that the event will have an impact on the transmission and increase it irrespective of the level of the prevalence. However, for low levels of prevalence and higher vaccination rates, this substantially decreases. Having computed the number of expected transmission events, we can then compute several complementary metrics of interest including for example the secondary attack rate (SAR) — that is, the number of COVID cases in the participants' community in both the null and the event model. SAR can be calculated from the predicted reproductive rate (R) in the regions where the ticket holders dwell. In the UK, R rates are updated on a weekly basis at regional levels (e.g. East Midlands, London etc) and available from the Office for National Statistics, or can be derived from the kNN modelling previously described. An opportunity for further research would be to estimate SAR within households by gathering contextual data from ticket holders. Equally, estimates of hospitalizations and deaths might be possible based on individual characteristics and comorbidities, however this is beyond the scope of the current article.

3. Evaluating the Effectiveness of the Screening Protocol

This risk modeling pipeline also allows comparison of different protocols and situations. For example, this pipeline highlights (a) the importance of event duration: the longer the dwell time at the event, the more at-risk the participants, and (b) the importance of wearing masks. Table 3 quantifies outcomes of holding the event on our three dates, assuming that either 0, 50 or 100% of participants are wearing masks, or varying parameters such as the density or length of the concert. Figure 4 completes that analysis by providing a visual representation the effect of these parameters on the distribution of the number of infections.

Figure 4: Effect of different input parameters on the distribution of the number of infections for an event at the RAH held on March 8th 2021.

Date of the Event	August 3 rd , 2020 (median, 95% CI)	January 18 th , 2021 (median, 95% CI)	March 8 th 2021 (median, 95% CI)
No mask 3h 5,000 participants	3.4 (1.9, 46.6)	131 (74, 1748)	36.4 (20.3, 485)
50% mask 3h 5,000 participants	1.7 (0.9, 23.8)	65 (36, 873)	17.7 (9.9, 226.2)
100% mask 3h 5,000 participants	0.5 (0.3, 6.8)	20 (11, 275)	5.4 (3.0, 71.3)
100% mask 1.5h 5,000 participants	0.3 (0.1, 3.3)	10 (5.6, 128)	2.6 (1.5, 35.7)
100% mask 3h 2,500 participants	0.2 (0.1, 2.3)	6.7 (3.8, 88.5)	1.8 (1.0, 24.4)

Table 3: Effect of different input parameters on the quantiles of the number of infections for an event at the RAH across all three dates.

In addition to the aggregated risk that a live event presents, individual risk of transmission can be estimated and can be communicated to ticket holders so that they can gauge whether the risk of attending the event outweighs their desire to attend. For the first person to purchase a ticket, risk of transmission will be calculated based on their own immunity status (vaccination, regional prevalence etc) and a synthetic population based on national prevalence at that time. As more bookings are assigned to ticket holders, the reliance on the synthetic population decreases as understanding of the number of susceptible and potentially infectious individuals attending the event increases. Therefore, the confidence in the risk score increases as the event draws closer and as the proportion of tickets sold increases. This can be reflected in the updated risk scores provided to ticket holders as the event approaches. The individual risk scores can be modified based on alternative scenarios imputed into the risk algorithm. For example, for an individual not yet vaccinated, their risk could be also presented as if they had been vaccinated, offering an opportunity for the individual to appreciate how vaccination could have modified their risk. Such an approach could form the basis for behaviour change interventional studies for promoting health literacy and tackling vaccine hesitancy (see Appendix D). By working in partnership with the live events organizer, individuals that chose to opt out can be reimbursed without delay and the ticket re-sold.

4. Discussion

The modelling we propose is based on prevalence estimates and screening protocols to calculate the number of infectious and susceptible individuals attending the event as well as transmission dynamics at the venue to predict the number of new infections. Our paper demonstrates the value of estimating attack rates from live events so that they can be appropriately managed. We also demonstrate how individual ticket holders can receive personalized risk scores for contracting COVID-19 at the event which would, for the first time, enable genuine informed consent to be obtained. Although this methodology provides clear benefit to event organizers, local public health authorities and individual ticket holders, our approach is based on several assumptions which group in two categories: modelling assumptions and parameter sensitivity.

Modelling Assumptions. As they combine data and tools from different sources, the computations in our pipeline rely on assumptions at three main levels:

(a) *Predicting COVID-19 prevalence.* To predict future COVID-19 incidence, we chose a kNN approach as it yields a more robust prediction and better uncertainty quantification than most existing parametric methods. One of the downsides of this approach is that it might not generalize very well to entirely novel behaviours or viral variants – in which case well-parameterized methods may outperform our approach as knowledge of transmission, vaccination and other relevant model parameters continues to improve. While prevalence predictions are important for event planners and attendees alike, on the day of the event the more important metric is whether official case rates reflect actual cases, i.e. the ascertainment rate. Historically, this rate has been low due to limited testing facilities, and our method to determine ascertainment using cases, deaths and infection-fatality rates reflects this, but also indicates that ascertainment may exceed 100% in times of widespread testing and low prevalence. It was beyond the scope of this paper to further investigate ascertainment but we expect that future research will clarify the impact of different test types, their false negative and positive rates, and their frequency of use in determining the ascertainment rate.

(b) *Assessing the efficiency of the screening protocol.* Our modelling framework assumes that events will screen participants with COVID-19 tests, such as virtually-witnessed lateral flow antigen tests. Assessing the efficiency of this screening step requires the estimation of (a) the sensitivity of the test, (b) the probability of having symptoms, and (c) the probability of being infectious – all of these quantities being a function of days since infection. Our estimation of each of these quantities is based on published data - with the exception of the probability of Symptom Check failure (i.e. the probability that a participant lies about their symptoms to get in). By default, we select this probability to be 50%, a choice that will be improved upon as the CAPACITY and other similar studies gather behavioural data. However, as shown in Appendix C, this factor has a relatively minor impact on the outcome of the model compared to the uncertainty of the other inputs. Of potentially greater concern is our assumption that the probability of testing negative 2 days before the event is independent (conditionally on time since infection) of a participant's infectiousness during the event. A potential avenue for improvement could consist of determining both test sensitivity and infectiousness as a function of viral load, and estimating the joint probability of the viral load 2 days apart. However, the data required for this approach is – to the best of our knowledge – still lacking, and given the variability of the viral load or PCR Ct behaviour, this conditional independence assumption seemed a reasonable first-order approximation.

(c) *Transmission at the event.* The airborne transmission model that we use relies on an homogeneous (well mixed) air hypothesis. While several other models have been proposed (either breaking the room into compartments or using a distance index) to counter (disprove or annul) this hypothesis, we highlight (following the discussion by Jimenez [69]) that this is a first order approximation: some participants will have more risk and others less, so that at low quanta concentration, this effect will be averaged out. At very high concentration, the model will likely under-estimate the number of infections, but given the efficiency of the screening protocol and density limitations, we do not expect this scenario to be common. Finally, we note that our model is not tied down to any specific transmission mechanism, and as our knowledge of COVID transmission improves, we can refine and supplant the transmission dynamics with a superior alternative or another model that is deemed more suitable.

Parameter Sensitivity. While we try to limit the number of input parameters in our pipeline, the sensitivity of the estimates to these inputs (namely, the mask efficiency and population of interest) has to be studied. We refer the reader to Appendix C for a quantitative sensitivity analysis and highlight our conclusions here. In terms of the model parameters, the greatest unknown consists in determining the efficiency of masks and protective

equipment - the latter having been shown to vary depending on the mask type and activity. However, we hope to make use of the growing body of literature on the topic to update and refine this important factor. Secondly, our prediction framework assumes that participants at the event have the same probability of infection and vaccination as their regional average. However this might not be the case as participation in the event may be an incentive to get vaccinated, or conversely might select for less cautious sub-populations. The importance of this sampling frame assumption nonetheless decreases as participants' vaccination status and behavioural data from the CAPACITY study will result in more precise estimates.

5. Conclusion

A nuanced, data-driven system is required to assess risk at each event informed by the characteristics of all ticket holders and the background risk of transmission concurrent to the event, so that proportionate and specific action can be taken by event organizers and public health authorities. We have detailed our attempt to create such a system and have outlined its predictions and limitations. Our end-to-end risk model is provided in the form of an R-shiny interface. At times of high prevalence, this type of system will ensure events likely to increase transmission can be halted. At times of low prevalence this will ensure events can potentially continue to operate. Learning to live with SARS-CoV-2 will be about implementing systems that support hyper-local, data driven decisions so that far-reaching and highly damaging sector-specific lockdowns can be avoided as much as possible.

Acknowledgments. The work of TE has been supported by the Estonian Research Council Grant PRG1291. MH and AEL are supported in part by the NW London NIHR Applied Research Collaboration. Imperial College London is grateful for support from the NW London NIHR Applied Research Collaboration and the Imperial NIHR Biomedical Research Centre. JK is currently Director of Health Optimisation at the Center for Health and Human Performance (London, UK), as well the co-founder and Medical Director of CERTIFIC.

Disclaimer. The views expressed in this publication are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care at Imperial College London, nor neither of any of the authors' corresponding institutions (University of Chicago, Carnegie Institution for Science, and University of Tartu).

References

- [1] Jie Lin, Kun Yan, Jingfeng Zhang, Ting Cai, and Jianjun Zheng. A super-spreader of covid-19 in ningbo city in china. *Journal of infection and public health*, 13(7):935–937, 2020.
- [2] Dasha Majra, Jayme Benson, Jennifer Pitts, and Justin Stebbing. Sars-cov-2 (covid-19) superspreader events. *Journal of Infection*, 2020.
- [3] Marine Nadal, Ludovic Lassel, Michel Denis, Aude Gibelin, Sandra Fournier, Laurent Menard, Hélène Goulet, Abdi Basma, Muriel Farthoukh, and Gilles Pialoux. Role of super-spreader phenomenon in a covid-19 cluster among healthcare workers in a primary care hospital. *The Journal of infection*, 2021.
- [4] Nathalie Charlotte. High rate of sars-cov-2 transmission due to choir practice in france at the beginning of the covid-19 pandemic. *Journal of Voice*, 2020.
- [5] David Atrubin, Michael Wiese, and Becky Bohinc. An outbreak of covid-19 associated with a recreational hockey game—florida, june 2020. *Morbidity and Mortality Weekly Report*, 69(41):1492, 2020.
- [6] Lea Hamner. High sars-cov-2 attack rate following exposure at a choir practice—skagit county, washington, march 2020. *MMWR. Morbidity and mortality weekly report*, 69, 2020.
- [7] Dyani Lewis. Superspreading drives the covid pandemic-and could help to tame it. *Nature*, 590(7847):544–546, 2021.
- [8] Alberto Gómez-Carballa, Xabier Bello, Jacobo Pardo-Seco, Federico Martín-Torres, and Antonio Salas. Mapping genome variation of sars-cov-2 worldwide highlights the impact of covid-19 super-spreaders. *Genome Research*, 30(10):1434–1448, 2020.

- [9] Yunjun Zhang, Yuying Li, Lu Wang, Mingyuan Li, and Xiaohua Zhou. Evaluating transmission heterogeneity and super-spreading event of covid-19 in a metropolis of china. *International journal of environmental research and public health*, 17(10):3705, 2020.
- [10] Marek Kochańczyk, Frederic Grabowski, and Tomasz Lipniacki. Super-spreading events initiated the exponential growth phase of covid-19 with 0 higher than initially estimated. *Royal Society open science*, 7(9):200786, 2020.
- [11] Yunjun Zhang, Yuying Li, Lu Wang, Mingyuan Li, and Xiaohua Zhou. Evaluating transmission heterogeneity and super-spreading event of covid-19 in a metropolis of china. *International journal of environmental research and public health*, 17(10):3705, 2020.
- [12] Georgia Tech. Covid-19 event risk assessment planning tool, 2020.
- [13] 19andme. Covid-19 event risk assessment planning tool, 2020.
- [14] abcnews. What’s your risk?, 2020.
- [15] mycovidrisk. My covid risk, 2020.
- [16] Illinois State Medical Society and the Illinois Medical Professionals Action Collaborative Team. Impact covid activity survey, 2020.
- [17] Texas Medical Association. Texmed risk assessment chart, 2020.
- [18] Texas Medical Association. Texmed holiday risk assessment chart, 2020.
- [19] Jos Lelieveld, Frank Helleis, Stephan Borrmann, Yafang Cheng, Frank Drewnick, Gerald Haug, Thomas Klimach, Jean Sciare, Hang Su, and Ulrich Pöschl. Model calculations of aerosol transmission and infection risk of covid-19 in indoor environments. *International Journal of Environmental Research and Public Health*, 17(21), 2020.
- [20] Rajat Mittal, Charles Meneveau, and Wen Wu. A mathematical framework for estimating risk of airborne transmission of covid-19 with application to face mask use and social distancing. *Physics of Fluids*, 32(10):101903, 2020.
- [21] Zhe Peng and Jose L Jimenez. Exhaled co2 as covid-19 infection risk proxy for different indoor environments and activities. *medRxiv*, 2020.
- [22] Nick Wilson, Stephen Corbett, and Euan Tovey. Airborne transmission of covid-19. *bmj*, 370, 2020.
- [23] the microCOVID Project. microcovid risk tracker, 2020.
- [24] Elizabeth Grenier. Could germany’s covid concert experiment help arenas hold large events again?, 2020.
- [25] Lucia Schulten. Dutch researchers test ways to party during the pandemic, 2021.
- [26] Covid: Barcelona hosts large gig after testing crowd, 2021.
- [27] Stefan Moritz, Cornelia Gottschick, Johannes Horn, Mario Popp, Susan Langer, Bianca Klee, Oliver Purschke, Michael Gekle, Angelika Ihling, and Rafael Mikolajczyk. The risk of indoor sports and culture events for the transmission of covid-19 (restart-19). *medRxiv*, 2020.
- [28] CDC. What you should know about the possibility of covid-19 illness after vaccination, 2021.
- [29] Ben Tinker and CNN Maggie Fox. So far, 5,800 fully vaccinated people have caught covid anyway in us, cdc says, year = 2021-04-13, url = <https://www.cnn.com/2021/04/14/health/breakthrough-infections-covid-vaccines-cdc/index.html>, urldate = 2021-05-01.
- [30] J Deeks, A Raffle, and M Gill. Covid-19: government must urgently rethink lateral flow test roll out. *BMJ Opinion*, 12, 2021.
- [31] The Guardian Josh Halliday. Rapid covid testing in england may be scaled back over false positives, year = 2021-04-15, url = <https://www.theguardian.com/world/2021/apr/15/rapid-covid-testing-in-england-may-be-scaled-back-over-false-positives>, urldate = 2021-05-01.

- [32] M Harris, J Kreindler, A El-Osta, T Esko, and F Majeed. Safe management of full-capacity live/mass events in covid19 will require mathematical, epidemiological and economic modelling. *Journal of the Royal Society of Medicine*, 2021.
- [33] Leo Beranek. *Concert halls and opera houses: music, acoustics, and architecture*. Springer Science & Business Media, 2012.
- [34] Kaustuv Chatterjee, Kaushik Chatterjee, Arun Kumar, and Subramanian Shankar. Healthcare impact of covid-19 epidemic in india: A stochastic mathematical model. *Medical Journal Armed Forces India*, 2020.
- [35] Alastair Grant. Dynamics of covid-19 epidemics: Seir models underestimate peak infection rates and overestimate epidemic duration. *medRxiv*, 2020.
- [36] Shaobo He, Yuexi Peng, and Kehui Sun. Seir modeling of the covid-19 and its dynamics. *Nonlinear Dynamics*, pages 1–14, 2020.
- [37] Gaurav Pandey, Poonam Chaudhary, Rajan Gupta, and Saibal Pal. Seir and regression model based covid-19 outbreak predictions in india. *arXiv preprint arXiv:2004.00958*, 2020.
- [38] Joseph T Wu, Kathy Leung, and Gabriel M Leung. Nowcasting and forecasting the potential domestic and international spread of the 2019-ncov outbreak originating in wuhan, china: a modelling study. *The Lancet*, 2020.
- [39] Shilei Zhao and Hua Chen. Modeling the epidemic dynamics and control of covid-19 outbreak in china. *Quantitative Biology*, pages 1–9, 2020.
- [40] Mohammad Akbarpour, Cody Cook, Aude Marzuoli, Simon Mongey, Abhishek Nagaraj, Matteo Saccarola, Pietro Tebaldi, Shoshana Vasserman, and Hanbin Yang. Socioeconomic network heterogeneity and pandemic policy response. *University of Chicago, Becker Friedman Institute for Economics Working Paper*, (2020-75), 2020.
- [41] Sheryl L Chang, Nathan Harding, Cameron Zachreson, Oliver M Cliff, and Mikhail Prokopenko. Modelling transmission and control of the covid-19 pandemic in australia. *arXiv preprint arXiv:2003.10218*, 2020.
- [42] De Kai, Guy-Philippe Goldstein, Alexey Morgunov, Vishal Nangalia, and Anna Rotkirch. Universal masking is urgent in the covid-19 pandemic: Seir and agent based models, empirical validation, policy recommendations. *arXiv preprint arXiv:2004.13553*, 2020.
- [43] Rebecca J Rockett, Alicia Arnott, Connie Lam, Rosemarie Sadsad, Verlaine Timms, Karen-Ann Gray, John-Sebastian Eden, Sheryl Chang, Mailie Gall, Jenny Draper, et al. Revealing covid-19 transmission in australia by sars-cov-2 genome sequencing and agent-based modeling. *Nature medicine*, 26(9):1398–1404, 2020.
- [44] Petrónio CL Silva, Paulo VC Batista, Hélder S Lima, Marcos A Alves, Frederico G Guimarães, and Rodrigo CP Silva. Covid-abs: An agent-based model of covid-19 epidemic to simulate health and economic effects of social distancing interventions. *Chaos, Solitons & Fractals*, 139:110088, 2020.
- [45] Jacco Wallinga and Marc Lipsitch. How generation intervals shape the relationship between growth rates and reproductive numbers. *Proceedings of the Royal Society B: Biological Sciences*, 274(1609):599–604, 2007.
- [46] Klaus Dietz. The estimation of the basic reproduction number for infectious diseases. *Statistical methods in medical research*, 2(1):23–41, 1993.
- [47] Jingjing He, Yifei Guo, Richeng Mao, and Jiming Zhang. Proportion of asymptomatic coronavirus disease 2019: A systematic review and meta-analysis. *Journal of medical virology*, 93(2):820–830, 2021.
- [48] Conor McAloon, Áine Collins, Kevin Hunt, Ann Barber, Andrew W Byrne, Francis Butler, Miriam Casey, John Griffin, Elizabeth Lane, David McEvoy, et al. Incubation period of covid-19: a rapid systematic review and meta-analysis of observational research. *BMJ open*, 10(8):e039652, 2020.

- [49] Jeroen JA van Kampen, David AMC van de Vijver, Pieter LA Fraaij, Bart L Haagmans, Mart M Lamers, Nisreen Okba, Johannes PC van den Akker, Henrik Endeman, Diederik AMPJ Gommers, Jan J Cornelissen, et al. Duration and key determinants of infectious virus shedding in hospitalized patients with coronavirus disease-2019 (covid-19). *Nature communications*, 12(1):1–6, 2021.
- [50] Lauren M Kucirka, Stephen A Lauer, Oliver Laeyendecker, Denali Boon, and Justin Lessler. Variation in false-negative rate of reverse transcriptase polymerase chain reaction-based sars-cov-2 tests by time since exposure. *Annals of internal medicine*, 173(4):262–267, 2020.
- [51] Ian W Pray. Performance of an antigen-based test for asymptomatic and symptomatic sars-cov-2 testing at two university campuses—wisconsin, september–october 2020. *MMWR. Morbidity and mortality weekly report*, 69, 2021.
- [52] Anika Singanayagam, Monika Patel, Andre Charlett, Jamie Lopez Bernal, Vanessa Saliba, Joanna Ellis, Shamez Ladhani, Maria Zamboni, and Robin Gopal. Duration of infectiousness and correlation with rt-pcr cycle threshold values in cases of covid-19, england, january to may 2020. *Eurosurveillance*, 25(32):2001483, 2020.
- [53] Xi He, Eric HY Lau, Peng Wu, Xilong Deng, Jian Wang, Xinxin Hao, Yiu Chung Lau, Jessica Y Wong, Yujuan Guan, Xinghua Tan, et al. Temporal dynamics in viral shedding and transmissibility of covid-19. *Nature medicine*, 26(5):672–675, 2020.
- [54] Claire Donnat, Nina Miolane, Freddy Bunbury, and Jack Kreindler. A bayesian hierarchical network for combining heterogeneous data sources in medical diagnoses. In *Machine Learning for Health*, pages 53–84. PMLR, 2020.
- [55] Public Health England. Impact of covid-19 vaccines on mortality in england: December 2020 to march 2021, 2021.
- [56] World Health Organization et al. Modes of transmission of virus causing covid-19: implications for ipc precaution recommendations: scientific brief, 27 march 2020. Technical report, World Health Organization, 2020.
- [57] Lidia Morawska and Donald K Milton. It is time to address airborne transmission of coronavirus disease 2019 (covid-19). *Clinical Infectious Diseases*, 71(9):2311–2313, 2020.
- [58] Dyani Lewis. Is the coronavirus airborne? experts can’t agree. *Nature*, 580(7802):175, 2020.
- [59] Hiroshi Nishiura, Hitoshi Oshitani, Tetsuro Kobayashi, Tomoya Saito, Tomimasa Sunagawa, Tamano Matsui, Takaji Wakita, MHLW COVID, Response Team, and Motoi Suzuki. Closed environments facilitate secondary transmission of coronavirus disease 2019 (covid-19). *MedRxiv*, 2020.
- [60] Sima Asadi, Nicole Bouvier, Anthony S Wexler, and William D Ristenpart. The coronavirus pandemic and aerosols: Does covid-19 transmit via expiratory particles?, 2020.
- [61] Renyi Zhang, Yixin Li, Annie L Zhang, Yuan Wang, and Mario J Molina. Identifying airborne transmission as the dominant route for the spread of covid-19. *Proceedings of the National Academy of Sciences*, 117(26):14857–14863, 2020.
- [62] Rajesh K Bhagat, MS Davies Wykes, Stuart B Dalziel, and PF Linden. Effects of ventilation on the indoor spread of covid-19. *Journal of Fluid Mechanics*, 903, 2020.
- [63] Shelly L Miller, William W Nazaroff, Jose L Jimenez, Atze Boerstra, Giorgio Buonanno, Stephanie J Dancer, Jarek Kurnitski, Linsey C Marr, Lidia Morawska, and Catherine Noakes. Transmission of sars-cov-2 by inhalation of respiratory aerosol in the skagit valley chorale superspreading event. *Indoor air*, 31(2):314–323, 2021.
- [64] Ahmed Elbanna, George N Wong, Zach J Weiner, Tong Wang, Hantao Zhang, Zhiru Liu, Alexei V Tkachenko, Sergei Maslov, and Nigel Goldenfeld. Entry screening and multi-layer mitigation of covid-19 cases for a safe university reopening. *medRxiv*, 2020.
- [65] Giorgio Buonanno, Luca Stabile, and Lidia Morawska. Estimation of airborne viral emission: Quanta emission rate of sars-cov-2 for infection risk assessment. *Environment International*, 141:105794, 2020.

- [66] Kevin P Fennelly. Particle sizes of infectious aerosols: implications for infection control. *The Lancet Respiratory Medicine*, 2020.
- [67] John T Brooks and Jay C Butler. Effectiveness of mask wearing to control community spread of sars-cov-2. *Jama*, 325(10):998–999, 2021.
- [68] Lynne Peeples. What the data say about wearing face masks. *Nature*, 586:186–189, 2020.
- [69] Jimenez. Aerosol transmission model, 2020.
- [70] Amelia Harrichandra, A Michael Ierardi, and Brian Pavilonis. An estimation of airborne sars-cov-2 infection transmission risk in new york city nail salons. *Toxicology and Industrial Health*, 36(9):634–643, 2020. PMID: 33085569.
- [71] EC Riley, G Murphy, and RL Riley. Airborne spread of measles in a suburban elementary school. *American journal of epidemiology*, 107(5):421–432, 1978.
- [72] William Firth Wells et al. Airborne contagion and air hygiene. an ecological study of droplet infections. *Airborne Contagion and Air Hygiene. An Ecological Study of Droplet Infections.*, 1955.
- [73] Gin Nam Sze To and Christopher Yu Hang Chao. Review and comparison between the wells–riley and dose-response approaches to risk assessment of infectious respiratory diseases. *Indoor air*, 20(1):2–16, 2010.
- [74] Brendan K Beare and Alexis Akira Toda. On the emergence of a power law in the distribution of covid-19 cases. *Physica D: Nonlinear Phenomena*, 412:132649, 2020.
- [75] Benjamin M Althouse, Edward A Wenger, Joel C Miller, Samuel V Scarpino, Antoine Allard, Laurent Hébert-Dufresne, and Hao Hu. Stochasticity and heterogeneity in the transmission dynamics of sars-cov-2. *arXiv preprint arXiv:2005.13689*, 2020.
- [76] Pasquale Cirillo and Nassim Nicholas Taleb. Tail risk of contagious diseases. *Nature Physics*, 16(6):606–613, 2020.
- [77] Thomas Obadia, Romana Haneef, and Pierre-Yves Boëlle. The r0 package: a toolbox to estimate reproduction numbers for epidemic outbreaks. *BMC medical informatics and decision making*, 12(1):1–9, 2012.
- [78] Zhian N Kamvar, Jun Cai, Juliet RC Pulliam, Jakob Schumacher, and Thibaut Jombart. Epidemic curves made easy using the r package incidence. *F1000Research*, 8, 2019.
- [79] Thibaut Jombart, Pierre Nouvellet, Sangeeta Bhatia, Zhian N Kamvar, Tim Taylor, and Stephane Ghazzi. Projections: Project future case incidence. 2020.
- [80] CJ Noakes, CB Beggs, PA Sleight, and KG Kerr. Modelling the transmission of airborne infections in enclosed spaces. *Epidemiology & Infection*, 134(5):1082–1091, 2006.
- [81] Shanbi Peng, Qikun Chen, and Enbin Liu. The role of computational fluid dynamics tools on investigation of pathogen transmission: Prevention and control. *Science of The Total Environment*, page 142090, 2020.
- [82] SN Rudnick and DK Milton. Risk of indoor airborne infection transmission estimated from carbon dioxide concentration. *Indoor air*, 13(3):237–245, 2003.
- [83] Kevin P Fennelly and Edward A Nardell. The relative efficacy of respirators and room ventilation in preventing occupational tuberculosis. *Infection Control & Hospital Epidemiology*, 19(10):754–759, 1998.
- [84] William W Nazaroff, Mark Nicas, and Shelly L Miller. Framework for evaluating measures to control nosocomial tuberculosis transmission. *Indoor Air*, 8(4):205–218, 1998.
- [85] Mark Nicas. An analytical framework for relating dose, risk, and incidence: an application to occupational tuberculosis infection. *Risk Analysis*, 16(4):527–538, 1996.

- [86] Michael Schuit, Shanna Ratnesar-Shumate, Jason Yolitz, Gregory Williams, Wade Weaver, Brian Green, David Miller, Melissa Krause, Katie Beck, Stewart Wood, Brian Holland, Jordan Bohannon, Denise Freeburger, Idris Hooper, Jennifer Biryukov, Louis A Altamura, Victoria Wahl, Michael Hevey, and Paul Dabisch. Airborne SARS-CoV-2 Is Rapidly Inactivated by Simulated Sunlight. *The Journal of Infectious Diseases*, 222(4):564–571, 06 2020.
- [87] Paul Dabisch, Michael Schuit, Artemas Herzog, Katie Beck, Stewart Wood, Melissa Krause, David Miller, Wade Weaver, Denise Freeburger, Idris Hooper, et al. The influence of temperature, humidity, and simulated sunlight on the infectivity of sars-cov-2 in aerosols. *Aerosol Science and Technology*, 55(2):142–153, 2021.
- [88] UK Parliament. Call for evidence in covid-19 certification inquiry, 2021.

A. Appendix: Prediction

As explained in the introduction, the aim of this paper is to develop a context-aware risk model: to be informative, the estimates of the risk that the model outputs must be informed by (a) the prevalence at the time of the event, (b) the ticket holders' vaccination status, and (c) the screening protocol employed by the event management to reduce transmission risk. In this setting, the CAPACITY protocol serves as a case in point and a motivation to our paper. Central to the study is the estimation of the risk associated with the event on two different horizons:

Horizon 1: Weeks prior to the event. In this setting, the goal is to predict ahead of time the risk associated with the event, and help organizers and ticket holders alike to plan ahead and decide whether or not they deem the risk associated with the event acceptable. This step requires the prediction of both the prevalence of the disease and the vaccination status of the crowd several weeks in advance.

Horizon 2: A few days before the event. The purpose of the risk estimation is to evaluate — with more certainty — the admissibility of the risk associated with the event. In this step, the algorithm can rely on ticket holders' reported vaccination status, as well as the most recent incidence rates to compute the risk.

Thus, whilst not crucial for Horizon 2 (in the last few days leading up to the event), the prediction of the crowd's vaccination status as well as the incidence rate are a major component of Horizon 1— thereby calling for prediction methods that both provide accurate estimates and a correct evaluation of their associated uncertainty. In this appendix, we focus on providing more details into the different predictive components that we use to estimate the risk ahead of time (Horizon 1). These consist of the following three main steps, which we subsequently describe in greater details:

- Step a: The prediction of the number of newly infected individuals who are ticket holders.
- Step b: The prediction of the number of infected participants that will escape the screening protocol.
- Step c: The prediction of the number of vulnerable ticket holders at the time of the event (i.e., participants that are not immune).

Step a. Prediction of new cases through a k-Nearest Neighbour (k-NN) Approach. The first step in our pipeline consists of the estimation of the daily incidence rate in the days leading to the event, which, in the main text of this paper, we suggested solving using a k -nearest neighbour approach with $k=100$. Indeed, this choice of $k=100$ neighbours allows us to have sufficient information to evaluate the percentiles of the distribution of the prediction, whilst retaining a sufficient amount of similarity with the original trajectory. The algorithm is described in details in Algorithm 1.

Data: Previous Incidence data $Y \in \mathbb{R}^{n \times T}$;

Choice of $k=100$;

Input vector $X \in \mathbb{R}^{p_{\text{train}}}$ with p_{train} the length of the training period;

p_{pred} the desired length of prediction period;

Result: k-Nearest Neighbors sample trajectories of length p_{pred} , average prediction and uncertainty estimates

Step 1: Compute the distance matrix :

for i in $1:n$ do

 for t in $1:T$ by 14 do

 Compute distance: $D_{\lfloor t/14 \rfloor + 1, i} = \text{distance}(X, Y_{(t-p_{\text{train}}+1):t})$;

 end

end

Step 2: Extract k nearest neighbours:

$\mathcal{I}, \mathcal{J}$ = Row and Column Indices of the k -smallest elements of D ;

Step 3: Recenter (translate) the prediction on start date to start the predicted trajectory:

$\hat{Y}[1 : p_{\text{pred}}] = \text{Mean}\left(Y[\mathcal{I}, \mathcal{J} : (\mathcal{J} + p_{\text{pred}})] + X[1] - Y[\mathcal{I}, \mathcal{J}]\right)$;

Algorithm 1: Prediction of the epidemic curve using k-NN

Motivation for the k-NN approach. COVID-19 prediction is undoubtedly an involved task — as denoted by the impressive amount of literature published on the topic [34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44]. Yet, as emphasized in the main text, many of these methods rely on a parametrization of the problem (Exponential growth, SEIR model, etc. [45, 46]) that require input parameters (eg, the reproductive number) that are both

unknown and non-stationary. Indeed, as the number of cases rises, policy makers are bound to adapt their policies to limit the spread of the virus. Reciprocally, as community prevalence levels drop, strict lockdown measures and stay-at-home orders are bound to be lifted — thus impacting the transmission modalities and likelihood of propagation of the virus. Incorporating both uncertainty and non-stationarity in predictions is thus a challenging task. Our solution to this problem relies on using a k-Nearest Neighbour approach (k-NN). To predict the trajectory of the epidemic in the next p_{pred} days, we use daily incidence (per hundred people) data from all countries around the world at any time during the epidemic, and look for the 100 curves that best match our country/region of interest in the past 28 days. This comparison is done using a simple ℓ_2 distance (we discuss in the following paragraph other choices of distances). The choice of 28 days is motivated by the fact that we need sufficient data to find trajectories with similar behaviours, whilst remaining sufficiently local for the comparison to be valid. Having found these 100 closest neighbours and translated them adequately to make them start at the observed value for the trajectory of interest on day 0, we use these 100 closest neighbours' observed trajectories in the next p_{pred} days to deduce an estimate for our future trajectory and an associated prediction interval. The underlying assumption here is that these observed 100-NN curves contain information both on the reproductive number and propensity of the epidemic to grow, but also on policy decisions made as a result of rising (or declining) prevalence numbers — thus making them an appealing non-parametric candidate for incidence modelling.

Performance and Benchmarking of the k-NN approach. To provide more substantial ground for our proposed kNN approach, we studied its performance compared to more traditional benchmarks using exponential growth model and Attack rate models [46, 45], commonly used in the literature and implemented in the R package R0 [77]. We compare a mix of classical projection methods, as well as k-Nearest Neighbour methods using various distances:

- The Attack Rate method [45], using the R package R0 [77], Incidence [78] and Projections[79],
- The Exponential Growth model [46] (using the same R packages),
- Our k-NN method, computing the distance between the training trajectory and the dataset using the ℓ_2 distance (we will denote this method by the “Sum of Squares”)
- Our k-NN method using a weighted ℓ_2 distance, in which the weights of observations are inversely proportional to the time since the origin of prediction (ie: for each day $k \in [1, p_{\text{train}}]$, $w_k = \frac{1}{p_{\text{train}} - k}$). This weighting of the observations puts more emphasis on more recent observations, so that trajectories that share a higher degree of similarity in their recent behaviours will be favoured by the algorithm. We will denote this method by “Weighted Sum of Squares”.
- Our k-NN method, computing the distance between the training trajectory and the dataset using a correlation measure between trajectories.
- Our k-NN method, computing the distance between the training trajectory and the dataset using a correlation-based distance, whilst giving more weight to recent observations (in a similar manner than for the “Weighted Sum of Squares” approach).

To compare these methods, we use data from "Our World in Data": for each country, we evaluate the performance of each method for predictions from June 1st 2020 to February 14th 2021. Every 28 days, we recreate a prediction scenario, in which we use 4 weeks of observations for training, and predict the daily incidence for the next four weeks. The purpose of this experiment is to assess and compare across methods (a) the mean square error as a measure of the methods' prediction accuracy, and (b) the coverage (percentage of times that the confidence interval covers the true observations), in order to establish which method allows to correctly estimate the uncertainty and risk. The results across countries and periods are provided in Figure 5a and the coverage is shown in Figure 5b. We see that the k-NN method achieves comparable MSE to the classical projection methods implemented in R. Yet, the k-NN method also achieves a coverage of more than 90% (and close to the nominal 95% that it targets), and the prediction interval that it provides is thus more reliable than that of other methods. Interestingly, we also note that the weighted and unweighted “Sum of Squares” k-NN achieve roughly the same performance. For the sake of simplicity, we thus use its unweighted counterpart.

Under-ascertainment bias. Having predicted the daily incidence rate in the weeks leading to the events, to correctly estimate the number of ticket holders that are likely to be contaminated, it is important to correct this prevalence estimate for any under-reporting bias. The under-ascertainment bias refers to the fact that the reported COVID cases are in fact an under-estimation of the actual number of cases, due to either

Figure 5: Performance of the different methods for predicting the epidemics trajectories (all countries around the world)

asymptomatic cases or limited testing capacities. In order to compute the appropriate correction, we use age-stratified estimates of the Infection-Fatality rate⁴. The method provided at this link has the advantage of computing robust IFR estimates by leveraging data from countries around the world, and adjusting for their demographic makeup. The actual number of cases is then computed as:

$$\text{bias}[t - \text{lag}] = \frac{\text{cases}[t - \text{lag}]}{\text{death}[t]} \times \text{IFR}$$

Indeed, since deaths are offset compared to the incidence rate, reported new cases must be compared to deaths roughly three weeks later (according to CDC reports). The under-ascertainment in the case of Britain is plotted in Figure 6a.

Step b. Estimating the Number of People who will escape the screening protocol. For the sake of clarity and to make this appendix self contained, we repeat here the discussion of the screening protocol provided in the main text, but provide additional detail on the estimation procedure. For an infectious individual to attend the event in spite of the CAPACITY study’ screening protocol, they must (a) have no COVID-like symptoms or fail to report them on the morning of the event, (b) receive a (false) negative result during antigen testing $D = 2$ days prior to the event, and (c) be contagious (rather than simply infected) at the time of the event.

(i) *Symptoms-Check Failure.* Indeed, one of the main challenges associated with the COVID-19 crisis is the number of asymptomatic cases - that is, infected individuals that do not express symptoms and are thus unaware of their potential infectiousness. This group encompasses people that are either pre-symptomatic or completely asymptomatic during the course of their illness – the latter are estimated to represent roughly 25% of all cases [47]. To account for this temporal dependency, we use estimates of the incubation period (defined as the number of days between infection and symptom onset) from McAloon et al. [48] and data on symptoms duration from van Kampen et al. [49] to estimate the probability for a ticket holder infected s days before the event to exhibit symptoms on the day of the event. We rely on simulations to estimate this probability distribution, finding estimates of the time to symptom onset by randomly generating an incubation period using data from McAloon et al. [48], and sampling a symptom duration from van Kampen et al. [49]. The resulting density plot is displayed in red in Figure 3a.

(ii) *Antigen test failure.* The sensitivity of COVID tests depends heavily on the time since infection, and whether these are the gold-standard PCR or Lateral Flow Antigen Assays [50]. Moreover, studies have shown that LFA tests have much lower sensitivity on asymptomatic individuals than symptomatic: in particular, according to a recent CDC report [51], Rapid Antigen testing has 80% sensitivity on symptomatic individuals, but only 40% sensitivity on asymptomatic individuals. Coupling the sensitivity estimates [50, 51] with the distribution of incubation period and estimated percentage of asymptomatic cases [48, 47], for each individual infected at day k taking an antigen test D days before the event, the probability of getting through the filtering protocol is thus given by the formula:

⁴The IFR have been taken from the following data source: <https://github.com/mbevand/covid19-age-stratified-ifr>

$$\begin{aligned} \mathbb{P}[\text{Protocol Fails} | \text{Contaminated at Time } k] = & \underbrace{(1 - s_{t-k-D}^{(\text{symptomatic})})(p_{SC} \times p_{t-k}^{(\text{symptom})} + (1 - p_{t-k}^{(\text{symptom})}))}_{\mathbb{P}[\{\text{Test with Symptom Fails}\} \cap \{\text{Symptom Check Fails}\}]} \\ & + \underbrace{p^{(\text{asymptomatic})} \times (1 - s^{(\text{asymptomatic})})}_{\mathbb{P}[\{\text{Asymptomatic}\} \cap \{\text{Test on Asymptomatics Fail}\}]} \end{aligned}$$

where $s_{t-k-D}^{(\text{symptomatic})}$ and $s^{(\text{asymptomatic})}$ are respectively the sensitivities of the test taken D days before the event for a symptomatic participant infected $t - k$ days before the event and an asymptomatic individual. The parameter $p_{t-k}^{(\text{symptom})}$ denotes the probability for a symptomatic individual to exhibit symptoms $t - k$ days after infection, whereas $p^{(\text{asymptomatic})}$ is the probability of being asymptomatic. Finally, the variable p_{SC} denotes the probability of the Symptoms Check failing — namely, that the participant does not want to report their symptom. Currently, this probability is set by default in our model to 50%, and we provide in our interactive dashboard the option to choose other levels. As the CAPACITY study gathers more behavioural data on the participants, we hope to improve this estimate. However, we study the sensitivity of our analysis to the choice of this variable in Appendix C, and show that in view of the total uncertainty surrounding other parameters in the model, the choice of this parameter does not severely affect the robustness of the results.

Figure 3b in the main text shows the probability of the failure of the screening protocol as a function of days after infection. This curve was also simulated by sampling: we model the uncertainty in the sensitivity through a set of Monte Carlo simulations, in which, for each simulation: (a) we sample a random sensitivity from a beta distribution, with parameters chosen to match the uncertainty intervals provided in [50], and (b) associate these random sensitivity to the probability of having symptoms and failing to report them. The shaded areas in Figure 3b denote the uncertainty around this estimate due to the variability of the incubation time.

(iii) *Estimating Infectiousness.* Infectiousness is a function of time since infection. Many articles in the literature have in particular estimated infectiousness to be at its peak within the first five days after symptom onset. However, very few reports provide an in-depth description of infectiousness as a function of time since infection. To this end, in this paper, we combine data from multiple sources. In particular, we rely on the data from Singanayagam et al [52]. Indeed, in this article, the authors study infectiousness as a function of time since symptom onset which they estimate by looking at the percentage of viable cultures that they can obtain from samples collected at various intervals before and after symptom onset. Since our goal is to consider infectiousness as a function of time since infection (rather than symptom onset), we combine this data with the estimated distribution of incubation length (duration between the date of infection, and date of symptom onset). One of the main issues in converting the data from [52] lies in the long tails of this distribution, which extrapolates from the data and allows samples to be highly contagious up to 10 days before infection. Since Singanayagam et al [52] have very few cases past 4 days prior since infection, we threshold infectiousness to 0 to be consistent with the estimates by He et al [53]. We compound the distribution of incubation and infectiousness by a probability of the incubation length, yielding a probability of infectiousness s days after infection such that:

$$\text{Infectiousness}_s = \sum_{i=1}^{\max(15, s-1)} \mathbb{P}[\text{Incubation Period} = i \text{ days}] \mathbb{P}[\text{Live Culture at day } s - i]$$

Step c: Estimating the number of people at risk. Finally, the last quantity that we need to impute is the number of people at risk during the event. As described in the main text, this requires a knowledge of the participants' COVID immunization status, i.e., has the participant already had COVID in the previous year and/or has the participant been vaccinated. This immunization status could be imputed through the combination of information regarding vaccination status as well as additional questions (previous positive test for COVID, symptoms, etc, combined in a model such as in [54]). However, for the sake of simplicity, we only consider here the vaccination status of the participants - thus leaving out the proportion of the population that has had COVID but has not been vaccinated yet. This induces a risk estimate that is biased upward — that is, we do not account for the immunity naturally gained by ticket holders through COVID infection —, and as such, is more conservative. When imputing the risk for Horizon 1 (a few weeks before the event, and without any ticket holders' information), we impute the event's crowd immunity level using linear regression. In other words, we assume that the number of new vaccinations (first and second dose) grows linearly each day, which amounts to assuming that vaccinations are operating at capacity. Figure 7 shows a plot of the cumulative number of first and second doses in the UK as a function of time, highlighting a good fit between the linear model and the

(a) Ascertainment rate for the United Kingdom. The y-axis denotes the ratio of detected cases to cases predicted by a linear model for the United Kingdom. by multiplying a 3-week shifted death rate by a calculated infection-fatality rate for the UK. When the values are less than one it suggests that many of the actual cases are not time as a covariate), with an associated R^2 of 0.92. As being detected, and when the values are greater than one time progresses, and vaccination rates increase, this linear it suggests that either a substantial proportion of cases are fit might start becoming less accurate, as problems of vaccine false positives or that survival from COVID infection has nation hesitancy or difficulty to access might induce vaccine increased from baseline predictions, due to better treatments centers to operate under capacity. or a greater bias towards infection of individuals at lower risk of death

Figure 6: Under-ascertainment rate (left) and vaccination rate (right) in the United Kingdom.

actual observations. We note though that as vaccination levels are increasing, the linear model will potentially have to be modified: after a certain proportion of the population has been vaccinated, vaccinations could stop operating at capacity since the remainder of the population could either have difficulties in gaining access to the vaccine, or could be opposed to the vaccine altogether. However, at the time of writing, the linear fit seems to be a good fit. Having imputed the rate of new vaccinations $\pi_{s=1 \dots t}$ in the days leading to the event, we turn to the estimation of the number of individuals that are likely to be susceptible. Recent reports indicate that vaccine-acquired immunity is a function of both time since vaccination and number of doses [55]. To compute the effective number of participants at risk in the event, we use a compound Poisson distribution: on each day s in the weeks leading to the event, the number X of new participants vaccinated (having either their first or second dose) is expressed as a $\text{Poisson}(\pi_s^{(\text{dose } j)})$, where $j \in \{1, 2\}$. Each of these newly vaccinated individuals then has a probability $\rho_{t-s}^{(\text{dose } j)}$ of being immune, depending on the date and dose j that they have received. The resulting number of immune people Z attending the event thus follows a Poisson model with rate: $Z \sim \text{Poisson}(\sum_{j=1}^2 \sum_{s=1}^T \pi_s^{(\text{dose } j)} \rho_{t-s}^{(\text{dose } j)})$.

However, as the number of vaccination increases, we expect the probability of the participants being immune to increase. In this case, we simply replace the Poisson binomial with a binomial, for various values of $\rho_{t-s}^{(\text{dose } j)}$ to allow the uncertainty around the immunity to percolate through the model.

B. Appendix: Transmission

In this appendix, we describe in greater details the model and assumptions made by the Jimenez aerosol transmission model proposed in [69, 63] and used to model transmission dynamics in the main text.

The issue of COVID transmission. As discussed in the main text, the precise mechanisms by which COVID-19 is transmitted are still unclear. Aside from direct physical contact, experts continue to debate the significance of the following two main routes of infection:

(a) *Droplet transmission.* In this scenario, transmission happens through the inhalation of droplets (particles of 5 to 10 μm in diameter [56]), and typically occurs when a person is in close proximity (within 1 meter) with someone who has respiratory symptoms (e.g. coughing or sneezing). In the context of live events, modelling this specific transmission route involves (a) modelling the distribution of the number of close contacts between infectious and susceptible ticket holders during the event and (b) modelling the transmission probability for

each close contact. The latter is a function of the proximity between participants and the amount of time spent in the vicinity of the infectious individual.

(b) *Airborne transmission*. Increasing concerns around airborne transmission have been raised by a number of experts over the past few months [57, 58]. Airborne transmission refers to the presence of the virus within droplet nuclei remaining in the air for long periods of time and with the potential to travel long distances [57] and penetrate more deeply in respiratory tracts. Airborne transmission has been estimated to be nearly 19 times more likely indoors than outdoors [59]. In the context of large public events, this transmission route thus has more diffusive power and hence could explain several super-spreader events (SSEs) [6] making it a major cause for concern [60, 61, 53, 62, 2, 57, 63, 64, 65, 66]. In this setting, infection risk is typically modelled using one of two distinct models: Wells-Riley equations and the dose-response model [80, 73]. First introduced by Riley in 1978 in a study of measles outbreak [71], the Wells-Riley equations are based on the concept of a hypothetical infectious unit called a "quantum of infection" [72], defined as the number of infectious airborne particles required to infect a person. Quanta aim to capture in a single parameter the rate of emission of viral particles in exhaled breath, the infectivity of the viruses upon emission, the particle size distribution of the emissions, the deposition efficiency and deposition location in the respiratory tract of the susceptible person, as well as the probability that deposition leads to infection. The dose-response model aims to describe more directly the effect on organisms from the exposure to different doses of chemicals, drugs, radiation, biological agents, or other stressors — and more recently to assess the infection risk of airborne transmissible pathogens. The review by Sze To et al [73] provides an in-depth comparison of the two models. In the context of COVID transmission, one of the main limitations of the dose-response model is that it relies on infectious dose data to derive the dose-response relationship. By contrast, many of the parameters in the Wells-Riley equation can be approximated and has thus been favored by many experts in the field [63, 70].

Choice of Transmission Route for this Model. While droplet emission is undeniably a source of concern and a major source of transmission, simple safety precautions such as mask wearing have been shown to efficiently control this transmission source [67, 68]: it is estimated that face masks can block 80% of exhaled droplets and reduce inhaled droplets by up to 50%, and so on average reduce the transmission probability by 70%. Conversely, the evidence concerning the efficiency of standard protective equipment in filtering aerosol droplets varies widely across studies probably due to "variation in experimental design and particle sizes analyzed" [67]. Airborne transmission in indoor settings can thus represent one of the main risk factors in live events, which we focus on modelling using the aerosol model proposed by Jimenez [69, 63]. The Jimenez aerosol transmission model [69, 81, 63] is indeed currently one of the only COVID-transmission models that provides enough granularity to quantify the risk associated with an event. This recognized model has been used several times in the literature over the course of the pandemic, including to allow in-class teaching at the University of Illinois at Chicago [64]. Based on the Wells-Riley model [72], this estimator calibrates the quanta to known transmission events, and takes into account important factors to compute a risk estimate, including event-specific (number of people, local prevalence, etc) and venue-specific variables (ventilation rate, size of the venue, UV exposure).

A core principle behind the Wells-Riley model is the notion of "quantum of infection". Exposure to one quantum of infection gives an average probability of $63\% = 1 - e^{-1}$ of becoming infected (essentially an infectious dose 63%, ID₆₃) [82]. The crux of the Wells-Riley equation consist in its modelling of the probability of infection P_I as a function of the ventilation, inhalation rates and quanta generation rates:

$$P_I = 1 - e^{-\frac{I n_I p t}{Q}} \quad (*)$$

where n_I is the number of infectors, p is the pulmonary ventilation rate of a person, q is the quanta generation rate, t is the exposure time interval, and Q is the room ventilation rate with clean air. Note that this equation is not dimensionless. As explained by Rudnick and Milton [82], q represents the generation rate of infectious doses, not organisms or infectious particles; it is the average infectious source strength of infected individual. Thus, the exponential form of the probability equation reflects the probability of a susceptible person in the room inhaling at least one quanta, based on a Poisson distribution of the number of discrete quanta inhaled by a susceptible person present in the space, given a certain aerosol quanta concentration in the room and an inhalation time.

One of the advantages of the Wells-Riley model is that many extensions have been studied, allowing the incorporation of additional influencing factors. In particular, the effect of respiratory protection can be considered by multiplying the term in the exponential by a fraction [83, 84, 85]:

$$P_I = 1 - \exp\left\{-R \frac{Iqpt}{Q}\right\} \quad (**)$$

where R is a number between 0 and 1 representing the fraction of particle penetration of the respiratory protection (it is in particular equal to 1 when no respirator is used). Other variables, such as the ultra-violet irradiation, particle filtration have been taken into account in the Wells-Riley equation through the equation:

$$P_I = 1 - \exp\left\{-\frac{Iqpt}{Q + \lambda_{UV}V + Q_r\eta_r}\right\} \quad (***)$$

where λ_{UV} is rate coefficient of inactivation by ultraviolet irradiation, V is the room volume, Q_r is the flow rate to the filter, and η_r is the filtration efficiency.

As suggested by Jimenez et al [69, 63], instead of modelling each of parameters in the Wells Riley equation explicitly, we can use the concept of quanta, and calibrate the emission rate to known outbreaks of the disease. We base the following description of the model as detailed by Jimenez et al [69, 63]. This model relies on the computation of three main components:

1. The Quanta Emission Rate. The quanta emission rate can be interpreted as the number of quanta emitted by unit of time by a single infectious participant. It can be modelled as:

$$q_e = \text{Quanta Exhalation Rate} \times (1 - \text{Mask Efficiency} * \mathbb{P}[\text{wear mask}]) \times n_{\text{infectious}}$$

2. The Quanta Concentration Rate. The quanta concentration rate q_c is computed as:

$$q_c = \frac{q_e}{\text{Loss} \times \text{Volume}} \times \left(1 - \frac{1}{\text{Loss} \times \text{Duration}} \times (1 - \exp\{-\text{Loss} \times \text{Duration}\})\right)$$

where q_e is the quanta emission rate and $n_{\text{infectious}}$ is the number of infectious people at the event. The loss corresponds to the first order loss:

Loss = Decay + Ventilation Rate with outside + Deposition Rate to surfaces + Additional Control Measures

The term "Decay" corresponds here to the decay rate of the virus, and is a function of the UV, temperature and relative humidity of the event. The Decay rate per hour is computed according to the following formula [86, 87] for which an open-source calculator is available online ⁵:

$$\begin{aligned} \text{Decay} = & (7.57 + 1.41 \times \frac{T - 20.54}{10.66} + 0.022 \times \frac{RH - 45.24}{28.67} + \\ & 7.55 \times (\frac{0.185UV}{50} - \frac{50}{10.66} + \frac{T - 20.54}{50} \frac{0.185UV - 50}{10.66} \times 1.40) \times 60 \end{aligned} \quad (1)$$

where T is the temperature and UV is the UV index. The tool is valid for the following ranges of conditions: 10 to 30°C (50-86°F), 20-70% relative humidity, and UV indices of 0-10. For live events in an indoor setting, the UV parameter should be set to 0.

We have checked that our computations are aligned with the figures provided in the references.

3. The Quanta Inhalation Rate. The quanta inhalation rate is computed as:

$$q_{\text{inhaled}} = q_{\text{concentration}} \times \text{Breathing Rate} * \text{Duration} \times (1 - \text{Mask Inhalation Efficiency} \times \mathbb{P}[\text{Wear Mask}])$$

Values for the Mask Inhalation Efficiency, as well as for the breathing rate (which varies by activity) can be found at the bottom of this page. For the sake of completeness and to make this manuscript self-contained, we have included the tables suggested by Jimenez [69] in Appendix E (Figures 12, 13, and 14), and refer to the sources he suggests for a more fine-grain estimate of what these should be⁶.

⁵This calculator can be found at the following link: <https://www.dhs.gov/science-and-technology/sars-airborne-calculator>

⁶Link to the EPA website: <https://www.epa.gov/expobox/exposure-factors-handbook-chapter-6>

(a) Decay rate as a function of UV and relative humidity, (b) Decay rate as a function of UV and temperature (in Celsius), for a relative humidity of 40% (Relative humidity is judged comfortable within ranges of 30 to 50%).

Figure 7: Decay rate of the virus, reproduced from [86, 87], and as a function of humidity, UV index, as well as temperature. NA values appear as transparent tiles.

Ventilation Rates. The ventilation rate per person is computed as:

$$\text{Ventilation} = \frac{1}{n_{\text{tot}}} \text{Volume} \times \text{Ventilation with outside air} \times \frac{1000}{3600} \quad (2)$$

where n_{tot} is the total number of participants, and the ventilation rate is measured in L^{-1}/s and depends on the activity. Again, for the sake of completeness, we have included in Appendix E (Figure 15) the table from the ASHRAE (American Society of Heating, Refrigerating and Air-Conditioning Engineers) listing all the activities as well as their corresponding ventilation rates⁷ that were suggested by Jimenez [69] to perform the computations.

C. Appendix: Sensitivity Analysis

Whilst we have based our estimates of the different parameters used in this model on the literature, and tried to incorporate estimates of their uncertainty to try and correctly estimate our confidence in the output of the model, this is nevertheless contingent on several choices on (a) the probability that a ticket holder will lie and fail to report symptoms on the day of the event in order to get into the event, and (b) the efficiency of the masks, and input parameters in the room.

(a) Probability of lying. As explained in the introduction, the risk model that we aim to develop has to be context-aware. That is, the estimates of the risk that the model should output should depend (a) on the prevalence at the time of the event and (b) on the ticket holder's vaccination status. The only input that requires to be determined is the propensity of people to lie if they have symptoms. This is a priori a difficult parameter to estimate, which would be required to be informed by sociology studies. As the CAPACITY study proceeds, this is in particular one of the parameters that we hope to be able to inform better. However, in the absence of information as to what value of that parameter should be set, we propose here a sensitivity analysis to show that the model is in fact relatively weakly sensitive to the choice of this particular parameter. We show the different infectiousness curves corresponding to different values of the parameter p_{lie} in Fig. 8 and 9. As shown in Fig. 8, this probability of lying impacts the value of the maximum probability of infectiousness at the event: this value is maximal at 4 days before the event, with a value of 42.1% if the participants never lie, 48% if these participants lie half of the time, and 53% if they always lie. This represents a 25.8% increase in probability from a scenario where participants are considered as completely trustworthy to one where these participants are considered as unreliable. Table 4 quantifies the impact of this parameter in the case of the Royal Albert Hall in order to assess the sensitivity of the entire pipeline to this particular choice of parameter in two situations: low prevalence (August 3rd 2020) and high prevalence (January 18th 2021). As denoted

⁷Link to the ASHRAE tables: https://ashrae.iwrapper.com/ASHRAE_PREVIEW_ONLY_STANDARDS/STD_62.1_2019

Figure 8: Analysis of the sensitivity of our infectiousness estimation to various values of the probability of lying.

in this table, the impact of this parameter is small in situations where the prevalence is already small. More substantial deviations occur when the prevalence increases, and such deviations are especially important in the tails (here, the median increases by 6 cases (35%) while the 97.5th prediction interval increased by 29% (69 cases) in situations of high prevalence between $p_{lie} = 0$ and $p_{lie} = 1$. While the relative increase (29%) is important, the absolute difference (69 cases) is small compared to the uncertainty in the prevalence (1245 (sd 375) cases).

	August 3rd, 2020			January 18th, 2021		
	Never Lies	50/50	Always Lies	Never Lies	50/50	Always Lies
Median	0.44	0.21	0.51	17	20	23
97.5 Quantile	5.63	6.81	7.42	222	264	311
99th Quantile	13.0	14.6	16.0	479	575	670

Table 4: Quantitative comparison of the sensitivity of the results (number of transmissions at the event) as a function of p_{SC} . While the absolute difference between the scenarios remains reasonable for the median, this difference becomes particularly important in the tails of the distribution (97.5th and 99th quantiles).

Mask Efficiency. Another parameter of great importance in the model consists of the effect of the mask efficiency. To this end, we contrast again a scenario with 100% of mandatory mask wearing, but with exhaled efficiency varying from 30, 50, 70, and 90% (the inhaled breathing being fixed efficiency to 50% – the same phenomenon would hold if varying the inhaled breathing efficiency). The results are presented in Table 5. We note the importance sensitivity of the results in the tails of the distribution: the absolute difference (in terms of number of cases) diverges significantly when looking at the 97.5th quantile of the distribution for instance. This highlights the efficiency of masks in limiting superspreading phenomena. We hope to use in particular the results of the CAPACITY study (and behavioural factors such as abidance to mask wearing, preferred type of mask, etc) as well as the growing literature of mask efficiency to be able to refine our estimate of the mask efficiency. In the meantime, in this paper, we use the conservative 70% efficiency (lower bound provided in [67]).

Discussion. In the modelling, we neglect any correlation between ticket holders, however this is unlikely to hold in real life as some might come from the same household. Given participants from the same household would all be rejected if one of them were to test positive, this simplification is likely to be a conservative estimate. Due to the nature of the problem and gaps in what is known about transmission risks, our model does not contend to make precise estimates of the form “we expect x numbers of cases” as a result of the event. Rather, it should be taken as a means of providing a scale of the risk and is best used to make comparisons, for example against a null model in which the event does not occur but individuals still get infected in the community. As such, our methodology provides a relative quantification of that risk such as “holding the

	August 3rd, 2020				January 18th, 2021			
Mask Efficiency (%)	30	50	70	90	30	50	70	90
Median	1.2	0.90	0.52	0.17	46.0	32.7	19.8	6.6
97.5 Quantile	16.3	11.0	6.1	2.3	607	440	264	89
99th Quantile	34.6	24.0	11.6	4.9	1351	959	566	202

Table 5: Sensitivity of the results to Mask efficiency. Note the significant absolute difference in the tails of the distribution.

event is expected to increase the number of cases by $x\%$ in this pool of participants.” The use of Monte Carlo simulations allow us to account for some uncertainty in our model, and to produce more meaningful risk estimates. As our second goal is to quantify the efficiency of the screening protocol, this pipeline can be run using different screening protocols or testing strategies to determine their efficiency. We also hope to be able to further develop this pipeline through (a) leveraging in-situ data collection and (b) refinement of the models themselves. In particular, using a fully anonymous, post-event questionnaire, we would evaluate participants’ compliance with the screening protocol, as well as with the safety measures at the time of the event. As more events are held, we can quantify the success of our pipeline to provide coverage of the observed number of infections. From the model perspective, we hope to explore further extensions to the current aerosol transmission model, which is based on the Wells-Riley model and so assumes uniform mixing of the quanta in the venue. Using information on the potential induced cases (e.g. their relative seating distance), we aim to refine this model by studying ways of accounting for the spatial heterogeneity of the quanta distribution.

D. Appendix: Risk Communication

Vaccine passports and widespread antigen tests – a false sense of security?. The use of vaccine passports for international air travel has ignited significant debate in the UK and even more controversial is their use for entry to mass, live events [12]. Notwithstanding the challenges surrounding operational verification of vaccine certification, the ethical implications of excluding those unable or unwilling to be vaccinated from participating in normal social encounters and the resulting implications for social inequities [13], the use of vaccine certification to permit entry to an event will likely significantly overestimate its safety. Vaccinated individuals may still be infected with SARS-CoV-2. Even antigen-test based screenings of ticket holders prior to an event will likely overestimate the safety of the event as some tests will be falsely negative. The definition of what constitutes an admissible level of risk thus poses a difficult conundrum to the live event industry.

CAPACITY-UK. The motivating application behind this paper is the CAPACITY study [32]— a partnership between CERTIFIC (a private, remote testing, health status and identify certification service), LiveNation (a live events production company) and Imperial College London – to predict and measure the outcomes of full capacity live events whilst ensuring rigorous abidance by public health and safety measures. Central to this study is the efficiency of pre-event screening by testing all ticket holders using professionally-witnessed rapid at-home antigen tests, and post-event monitoring based on antigen tests, surveys and safety recommendations. Mass rollout of home-based Lateral Flow Testing to all adults in the UK [88] for twice weekly testing ensures that all households will already have the tests available to them. CAPACITY-UK proposes simply for the tests to be professionally witnessed via the CERTIFIC application to overcome the trust issue, verifying that tests have been collected and conducted to the appropriate standard. In addition to testing (which is susceptible to false positives and negatives), the CAPACITY protocol gathers anonymized information on participant vaccination status, regional address, and a few basic questions regarding individual characteristics (see Fig. 10). The purpose of this additional information is to allow the design of a tailored risk estimation model — both at the participant and at the community level. Such risk estimates are central to the protocol: not only are they necessary in the context of informed consent and communicating to the ticket holders their own level of risk so that they may choose to attend the event, they are essential in informing event managers and policy makers on the likelihood of an outbreak. This system potentially allows for the management of full capacity, live events – a crucial parameter for commercial viability of the industry. Moreover, contrary to the issues surrounding vaccination passports, vaccination status would be requested, but not required for attendance – particularly if overall risk of transmission at the event remains within acceptable bounds.

This system potentially allows for the management of full capacity, live events – a crucial parameter for commercial viability of the industry. Moreover, contrary to the issues surrounding vaccination passports, vac-

Figure 10: CAPACITY process flow from the ticket holder perspective. On the left hand side in red lined boxes are the timings of various stages in CAPACITY process flow. In the middle the process flow is described from the participant perspective. On the right hand side the interaction between user-supplied data and model-generated risk estimates is described. The certainty in the model output is conveyed through the varying shades of grey (the darker the colour, the more certain the model).

cination status would be requested, but not required for attendance – particularly if overall risk of transmission at the event remains within acceptable bounds.

Risk Communication.. The risk estimate is then provided to the participants using a variety of different formats, for better interpretability and communicability of the risk to the general public. Fig 11 shows a few examples of the displays used by the CAPACITY study.

Figure 11: Top left – baseline estimates; Top right – final estimates; Bottom left – individual risk communication; Bottom right – tailored risk scores under different scenarios

E. Appendix: Reference Tables

Table 6-1. Recommended Long-Term Exposure Values for Inhalation (males and females combined)					
Age Group ^a	Mean (m ³ /day)	Sources Used for Means	95 th Percentile ^b (m ³ /day)	Sources Used for 95 th Percentiles	Multiple Percentiles
Birth to <1 month	3.6	c	7.1	c	
1 to <3 months	3.5	c, d	5.8	c, d	
3 to <6 months	4.1	c, d	6.1	c, d	
6 to <12 months	5.4	c, d	8.0	c, d	
Birth to <1 year	5.4	c, d, e, f	9.2	c, d, e	
1 to <2 years	8.0	c, d, e, f	12.8	c, d, e	
2 to <3 years	8.9	c, d, e, f	13.7	c, d, e	
3 to <6 years	10.1	c, d, e, f	13.8	c, d, e	See Table 6-4, Table 6-6 through Table 6-8, Table 6-10, Table 6-14 Table 6-15 [none available for Stifelman (2007)]
6 to <11 years	12.0	c, d, e, f	16.6	c, d, e	
11 to <16 years	15.2	c, d, e, f	21.9	c, d, e	
16 to <21 years	16.3	c, d, e, f	24.6	c, d, e	
21 to <31 years	15.7	d, e, f	21.3	d, e	
31 to <41 years	16.0	d, e, f	21.4	d, e	
41 to <51 years	16.0	d, e, f	21.2	d, e	
51 to <61 years	15.7	d, e, f	21.3	d, e	
61 to <71 years	14.2	d, e, f	18.1	d, e	
71 to <81 years	12.9	d, e	16.6	d, e	
≥81 years	12.2	d, e	15.7	d, e	
^a	When age groupings in the original reference did not match the U.S. EPA groupings used for this handbook, means from all age groupings in the original reference that overlapped U.S. EPA's age groupings by more than one year were averaged, weighted by the number of observations contributed from each age group. Similar calculations were performed for the 95 th percentiles. See Table 6-25 for concordance with U.S. EPA age groupings.				
^b	Some 95 th percentile values may be unrealistically high and not representative of the average person.				
^c	Arcus-Arth and Blaisdell (2007).				
^d	Brochu et al. (2006b).				
^e	U.S. EPA (2009a).				
^f	Stifelman (2007).				

Figure 12: Inhalation Rates. Link to the EPA website: <https://www.epa.gov/expobox/exposure-factors-handbook-chapter-6>

Table 6-2. Recommended Short-Term Exposure Values for Inhalation (males and females combined) (continued)				
Activity Level	Age Group (year)	Mean (m ³ /minute)	95 th Percentile (m ³ /minute)	Multiple Percentiles
Light Intensity (continued)	21 to <31	1.2E-02	1.6E-02	
	31 to <41	1.2E-02	1.6E-02	
	41 to <51	1.3E-02	1.6E-02	
	51 to <61	1.3E-02	1.7E-02	
	61 to <71	1.2E-02	1.6E-02	
	71 to <81	1.2E-02	1.5E-02	
	≥81	1.2E-02	1.5E-02	
Moderate Intensity	Birth to <1	1.4E-02	2.2E-02	
	1 to <2	2.1E-02	2.9E-02	
	2 to <3	2.1E-02	2.9E-02	
	3 to <6	2.1E-02	2.7E-02	
	6 to <11	2.2E-02	2.9E-02	
	11 to <16	2.5E-02	3.4E-02	
	16 to <21	2.6E-02	3.7E-02	
	21 to <31	2.6E-02	3.8E-02	
	31 to <41	2.7E-02	3.7E-02	
	41 to <51	2.8E-02	3.9E-02	
	51 to <61	2.9E-02	4.0E-02	
	61 to <71	2.6E-02	3.4E-02	
	71 to <81	2.5E-02	3.2E-02	
	≥81	2.5E-02	3.1E-02	
High Intensity	Birth to <1	2.6E-02	4.1E-02	
	1 to <2	3.8E-02	5.2E-02	
	2 to <3	3.9E-02	5.3E-02	
	3 to <6	3.7E-02	4.8E-02	
	6 to <11	4.2E-02	5.9E-02	
	11 to <16	4.9E-02	7.0E-02	
	16 to <21	4.9E-02	7.3E-02	
	21 to <31	5.0E-02	7.6E-02	
	31 to <41	4.9E-02	7.2E-02	
	41 to <51	5.2E-02	7.6E-02	
	51 to <61	5.3E-02	7.8E-02	
	61 to <71	4.7E-02	6.6E-02	
	71 to <81	4.7E-02	6.5E-02	
	≥81	4.8E-02	6.8E-02	

Figure 13: Inhalation Rates. Link to the EPA website: <https://www.epa.gov/expobox/exposure-factors-handbook-chapter-6>

Table 6-2. Recommended Short-Term Exposure Values for Inhalation (males and females combined)				
Activity Level	Age Group (years)	Mean (m ³ /minute)	95 th Percentile (m ³ /minute)	Multiple Percentiles
Sleep or Nap	Birth to <1	3.0E-03	4.6E-03	See Table 6-17 and Table 6-19
	1 to <2	4.5E-03	6.4E-03	
	2 to <3	4.6E-03	6.4E-03	
	3 to <6	4.3E-03	5.8E-03	
	6 to <11	4.5E-03	6.3E-03	
	11 to <16	5.0E-03	7.4E-03	
	16 to <21	4.9E-03	7.1E-03	
	21 to <31	4.3E-03	6.5E-03	
	31 to <41	4.6E-03	6.6E-03	
	41 to <51	5.0E-03	7.1E-03	
	51 to <61	5.2E-03	7.5E-03	
	61 to <71	5.2E-03	7.2E-03	
	71 to <81	5.3E-03	7.2E-03	
	≥81	5.2E-03	7.0E-03	
Sedentary/ Passive	Birth to <1	3.1E-03	4.7E-03	
	1 to <2	4.7E-03	6.5E-03	
	2 to <3	4.8E-03	6.5E-03	
	3 to <6	4.5E-03	5.8E-03	
	6 to <11	4.8E-03	6.4E-03	
	11 to <16	5.4E-03	7.5E-03	
	16 to <21	5.3E-03	7.2E-03	
	21 to <31	4.2E-03	6.5E-03	
	31 to <41	4.3E-03	6.6E-03	
	41 to <51	4.8E-03	7.0E-03	
	51 to <61	5.0E-03	7.3E-03	
	61 to <71	4.9E-03	7.3E-03	
	71 to <81	5.0E-03	7.2E-03	
	≥81	4.9E-03	7.0E-03	
Light Intensity	Birth to <1	7.6E-03	1.1E-02	
	1 to <2	1.2E-02	1.6E-02	
	2 to <3	1.2E-02	1.6E-02	
	3 to <6	1.1E-02	1.4E-02	
	6 to <11	1.1E-02	1.5E-02	
	11 to <16	1.3E-02	1.7E-02	
	16 to <21	1.2E-02	1.6E-02	

Figure 14: Inhalation Rates. Link to the EPA website: <https://www.epa.gov/expobox/exposure-factors-handbook-chapter-6>

TABLE 6.2.2.1 Minimum Ventilation Rates in Breathing Zone
(Table 6.2.2.1 shall be used in conjunction with the accompanying notes.)

Occupancy Category	People Outdoor Air Rate R_p		Area Outdoor Air Rate R_a		Notes	Default Values			
	cfm/ person	L/s/ person	cfm/ft ²	L/s·m ²		Occupant Density (see Note 4)	Combined Outdoor Air Rate (see Note 5)		Air Class
						#/1000 ft ² or #/100 m ²	cfm/ person	L/s· person	
Correctional Facilities									
Cell	5	2.5	0.12	0.6		25	10	4.9	2
Dayroom	5	2.5	0.06	0.3		30	7	3.5	1
Guard stations	5	2.5	0.06	0.3		15	9	4.5	1
Booking/waiting	7.5	3.8	0.06	0.3		50	9	4.4	2
Educational Facilities									
Daycare (through age 4)	10	5	0.18	0.9		25	17	8.6	2
Daycare sickroom	10	5	0.18	0.9		25	17	8.6	3
Classrooms (ages 5–8)	10	5	0.12	0.6		25	15	7.4	1
Classrooms (age 9 plus)	10	5	0.12	0.6		35	13	6.7	1
Lecture classroom	7.5	3.8	0.06	0.3	H	65	8	4.3	1
Lecture hall (fixed seats)	7.5	3.8	0.06	0.3	H	150	8	4.0	1
Art classroom	10	5	0.18	0.9		20	19	9.5	2
Science laboratories	10	5	0.18	0.9		25	17	8.6	2
University/college laboratories	10	5	0.18	0.9		25	17	8.6	2
Wood/metal shop	10	5	0.18	0.9		20	19	9.5	2
Computer lab	10	5	0.12	0.6		25	15	7.4	1
Media center	10	5	0.12	0.6	A	25	15	7.4	1
Music/theater/dance	10	5	0.06	0.3	H	35	12	5.9	1
Multiuse assembly	7.5	3.8	0.06	0.3	H	100	8	4.1	1

Figure 15: Ventilation Rates taken from the ASHRAE standards ⁸